SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2014Drug-drug interactions between bedaquiline and the antiretrovirals nevirapine and lopinavir/ritonavir in patients - M. PandieView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2014The Critical Path to TB Drug Regimens: Advancing through a Multidisciplinary, Multipartner Approach - Klaus Romero, MD, MSView Slideset
SNSharon NachmanMDSlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2014Clinical Pharmacology Issues for Pediatric TB - Sharon Nachman, MDView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2014Pharmacokinetics of rifampin among pregnant women with tuberculosis and HIV co-infection - K. DooleyView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2014A simultaneous population pharmacokinetic analysis in Malawian adults and children of rifampicin - A. SchipaniView Slideset
SNSharon NachmanMDSlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2014Pharmacokinetics of rifampicin, isoniazid and pyrazinamide in children on 2010 WHO/IUATLD guideline doses - H. McIlleronView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015Quantitative modeling of time to positivity following dosing of bedaquiline and rifafour in patients with pulmonary tuberculosis infection - J.F. MarierView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015Drug Partitioning and Local Microenvironmental Conditions affect Bedaquiline, Clofazimine and Pyrazinamide Treatment Responses in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice - S. IrwinView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015Prediction of drug partitioning into tubercular pulmonary lesions - C. ChenView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015Digitizing MTB Medicines: Using compounding methods to enable mobile capture of MTB medication adherence - S. BrowneView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015TB and Diabetes Mellitus: Pharmacological Aspects of the Convergence of Two Epidemics - Rovina Ruslami, MD, PhDView Slideset
SlidesetInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015Mathematical model of drug-target binding predicts optimal antibiotic treatment - P. Abel zur WieschView Slideset
